275 related articles for article (PubMed ID: 24469854)
1. Factors impacting survival following second surgery in patients with glioblastoma in the temozolomide treatment era, incorporating neutrophil/lymphocyte ratio and time to first progression.
McNamara MG; Lwin Z; Jiang H; Templeton AJ; Zadeh G; Bernstein M; Chung C; Millar BA; Laperriere N; Mason WP
J Neurooncol; 2014 Mar; 117(1):147-52. PubMed ID: 24469854
[TBL] [Abstract][Full Text] [Related]
2. Temozolomide for high grade glioma.
Hart MG; Garside R; Rogers G; Stein K; Grant R
Cochrane Database Syst Rev; 2013 Apr; 2013(4):CD007415. PubMed ID: 23633341
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of temozolomide treatment used at the same time with radiotherapy and adjuvant temozolomide; concomitant therapy of glioblastoma multiforme: multivariate analysis and other prognostic factors.
Birol Sarica F; Tufan K; Cekinmez M; Sen O; Cem Onal H; Mertsoylu H; Topkan E; Pehlivan B; Erdogan B; Nur Altinors M
J Neurosurg Sci; 2010 Mar; 54(1):7-19. PubMed ID: 20436394
[TBL] [Abstract][Full Text] [Related]
4. Neutrophil-lymphocyte ratio dynamics during concurrent chemo-radiotherapy for glioblastoma is an independent predictor for overall survival.
Mason M; Maurice C; McNamara MG; Tieu MT; Lwin Z; Millar BA; Menard C; Laperriere N; Milosevic M; Atenafu EG; Mason W; Chung C
J Neurooncol; 2017 May; 132(3):463-471. PubMed ID: 28332000
[TBL] [Abstract][Full Text] [Related]
5. Clinical, Radiographic, and Pathologic Findings in Patients Undergoing Reoperation Following Radiation Therapy and Temozolomide for Newly Diagnosed Glioblastoma.
Ellsworth S; Ye X; Grossman SA
Am J Clin Oncol; 2017 Jun; 40(3):219-222. PubMed ID: 26491903
[TBL] [Abstract][Full Text] [Related]
6. The Prognostic Value of the Pretreatment Neutrophil/Lymphocyte Ratio in Patients with Glioblastoma Multiforme Brain Tumors: A Retrospective Cohort Study of Patients Treated with Combined Modality Surgery, Radiation Therapy, and Temozolomide Chemotherapy.
Brenner A; Friger M; Geffen DB; Kaisman-Elbaz T; Lavrenkov K
Oncology; 2019; 97(5):255-263. PubMed ID: 31288238
[TBL] [Abstract][Full Text] [Related]
7. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
8. Favorable prognosis in patients with high-grade glioma with radiation necrosis: the University of Colorado reoperation series.
Rusthoven KE; Olsen C; Franklin W; Kleinschmidt-DeMasters BK; Kavanagh BD; Gaspar LE; Lillehei K; Waziri A; Damek DM; Chen C
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):211-7. PubMed ID: 20732762
[TBL] [Abstract][Full Text] [Related]
9. Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival?
Boiardi A; Silvani A; Eoli M; Lamperti E; Salmaggi A; Gaviani P; Fiumani A; Botturi A; Falcone C; Solari A; Filippini G; Di Meco F; Broggi G
J Neurooncol; 2008 May; 88(1):105-13. PubMed ID: 18283418
[TBL] [Abstract][Full Text] [Related]
10. Radiochemotherapy with temozolomide for patients with glioblastoma. Prognostic factors and long-term outcome of unselected patients from a single institution.
Gerstein J; Franz K; Steinbach JP; Seifert V; Rödel C; Weiss C
Strahlenther Onkol; 2011 Nov; 187(11):722-8. PubMed ID: 22037649
[TBL] [Abstract][Full Text] [Related]
11. A Cumulative Score Based on Preoperative Neutrophil-Lymphocyte Ratio and Fibrinogen in Predicting Overall Survival of Patients with Glioblastoma Multiforme.
Hao Y; Li X; Chen H; Huo H; Liu Z; Tian F; Chai E
World Neurosurg; 2019 Aug; 128():e427-e433. PubMed ID: 31042598
[TBL] [Abstract][Full Text] [Related]
12. Low-dose rate stereotactic iodine-125 brachytherapy for the treatment of inoperable primary and recurrent glioblastoma: single-center experience with 201 cases.
Kickingereder P; Hamisch C; Suchorska B; Galldiks N; Visser-Vandewalle V; Goldbrunner R; Kocher M; Treuer H; Voges J; Ruge MI
J Neurooncol; 2014 Dec; 120(3):615-23. PubMed ID: 25151509
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma.
Clarke JL; Iwamoto FM; Sul J; Panageas K; Lassman AB; DeAngelis LM; Hormigo A; Nolan CP; Gavrilovic I; Karimi S; Abrey LE
J Clin Oncol; 2009 Aug; 27(23):3861-7. PubMed ID: 19506159
[TBL] [Abstract][Full Text] [Related]
14. Hypofractionated radiotherapy with or without concurrent temozolomide in elderly patients with glioblastoma multiforme: a review of ten-year single institutional experience.
Cao JQ; Fisher BJ; Bauman GS; Megyesi JF; Watling CJ; Macdonald DR
J Neurooncol; 2012 Apr; 107(2):395-405. PubMed ID: 22105851
[TBL] [Abstract][Full Text] [Related]
15. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.
Brada M; Hoang-Xuan K; Rampling R; Dietrich PY; Dirix LY; Macdonald D; Heimans JJ; Zonnenberg BA; Bravo-Marques JM; Henriksson R; Stupp R; Yue N; Bruner J; Dugan M; Rao S; Zaknoen S
Ann Oncol; 2001 Feb; 12(2):259-66. PubMed ID: 11300335
[TBL] [Abstract][Full Text] [Related]
16. Conditional probability of survival and post-progression survival in patients with glioblastoma in the temozolomide treatment era.
McNamara MG; Lwin Z; Jiang H; Chung C; Millar BA; Sahgal A; Laperriere N; Mason WP
J Neurooncol; 2014 Mar; 117(1):153-60. PubMed ID: 24469855
[TBL] [Abstract][Full Text] [Related]
17. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-2010 in Spain.
Graus F; Bruna J; Pardo J; Escudero D; Vilas D; Barceló I; Brell M; Pascual C; Crespo JA; Erro E; García-Romero JC; Estela J; Martino J; García-Castaño A; Mata E; Lema M; Gelabert M; Fuentes R; Pérez P; Manzano A; Aguas J; Belenguer A; Simón A; Henríquez I; Murcia M; Vivanco R; Rojas-Marcos I; Muñoz-Carmona D; Navas I; de Andrés P; Mas G; Gil M; Verger E
Neuro Oncol; 2013 Jun; 15(6):797-805. PubMed ID: 23460319
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B
Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients: A single-center analysis.
Roh TH; Park HH; Kang SG; Moon JH; Kim EH; Hong CK; Ahn SS; Choi HJ; Cho J; Kim SH; Lee SK; Kim DS; Kim SH; Suh CO; Lee KS; Chang JH
Medicine (Baltimore); 2017 Jul; 96(27):e7422. PubMed ID: 28682902
[TBL] [Abstract][Full Text] [Related]
20. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.
Sampson JH; Heimberger AB; Archer GE; Aldape KD; Friedman AH; Friedman HS; Gilbert MR; Herndon JE; McLendon RE; Mitchell DA; Reardon DA; Sawaya R; Schmittling RJ; Shi W; Vredenburgh JJ; Bigner DD
J Clin Oncol; 2010 Nov; 28(31):4722-9. PubMed ID: 20921459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
